Genmab — April 2015
-
Det skal nok give anledning til uro.
-
Iplanneren kan ses her https://iplanner.asco.org/am2015
-
Spændende med abstract release
-
Spændende at data kommer på ASCO sukker. Omvendt havde de været mega gode skulle Gilead vel også lave en pressemeddelelse?
-
Hvis de mente de ville være kurspåvirkende
-
Men dejligt endeligt at få de kombi data så vi ikke skal vente længere
-
enig. Men genmab får nok ikke data fra Gilead før de er præsenteret.
-
Zydelic solgte for 6 mio. $ i Q3 og 17 mio. i Q4 aner ikke hvad forventningerne var
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind